Gilead Sciences is getting global rights to an experimental PepStar Therapeutics oral peptide designed to inhibit the IL-23 receptor to treat inflammatory bowel disease. It could compete against Johnson & Johnson’s Icotyde, an oral peptide that blocks the same target and is also in development for IBD.

The post Gilead to Pay $1.3B for Oral Peptide That Could Rival J&J’s New Immunology Pill appeared first on MedCity News.